AGMB AgomAb Therapeutics NV
$8.40▼ -1.98%
Healthcare
Other
After hours
$8.40▲ +0.00%
Oct 27, 4:00 PM ET
Volume 89.8K
Avg Volume (10D) 61.1K
Key Metrics & Fundamentals
Market Cap
$413.68M
P/E Ratio
–
Div Yield
0.00%
52W Range
7.88 - 17.82
% vs 50 MA
-25.47%
% vs 200 MA
–%
RSI-14
36.0
MACD Histogram
+0.1400
Beta (1Y vs SPY)
1.78
Free Cash Flow
-$13.18M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$17.62M
COGS
–
Operating Exp
$16.53M
Operating Income
-$16.53M
EBIT
-$16.53M
Pretax Income
-$17.40M
Net Income
-$17.40M
Price & Volume History
Loading chart…
Recent News
Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease
GlobeNewswire · Oct 13, 2026 4:05 PM ET
Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation
GlobeNewswire · Oct 8, 2026 4:05 PM ET
Agomab stock jumps on positive trial data
Investing.com · Oct 1, 2026 9:27 AM ET
Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease
GlobeNewswire · Oct 1, 2026 6:30 AM ET
Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study
GlobeNewswire · Sep 14, 2026 4:05 PM ET
Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
GlobeNewswire · Sep 11, 2026 4:05 PM ET
Agomab to Participate in Upcoming Investor Conferences
GlobeNewswire · Sep 3, 2026 4:05 PM ET
Cantor Fitzgerald Initiates AgomAb Therapeutics at Overweight
MT Newswires · Aug 19, 2026 6:47 AM ET
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
GlobeNewswire · Aug 10, 2026 4:07 PM ET
Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook
GlobeNewswire · Aug 6, 2026 4:01 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See AGMB's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.